Cancel anytime
Corcept Therapeutics Incorporated (CORT)
- BUY Advisory
- Profitable SELL
- Loss-Inducing SELL
- Profit
- Loss
- PASS (Skip invest)*
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
12/09/2024: CORT (4-star) is a STRONG-BUY. BUY since 61 days. Profits (55.50%). Updated daily EoD!
Analysis of Past Performance
Type: Stock | Upturn Star Rating | Today’s Advisory: Strong Buy |
Historic Profit: 31.67% | Upturn Advisory Performance 3 | Avg. Invested days: 30 |
Profits based on simulation | Stock Returns Performance 3 | Last Close 12/09/2024 |
Type: Stock | Today’s Advisory: Strong Buy |
Historic Profit: 31.67% | Avg. Invested days: 30 |
Upturn Star Rating | Stock Returns Performance 3 |
Profits based on simulation Last Close 12/09/2024 | Upturn Advisory Performance 3 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 6.21B USD |
Price to earnings Ratio 47.03 | 1Y Target Price 74.9 |
Dividends yield (FY) - | Basic EPS (TTM) 1.26 |
Volume (30-day avg) 1021224 | Beta 0.46 |
52 Weeks Range 20.84 - 62.22 | Updated Date 12/9/2024 |
Company Size Mid-Cap Stock | Market Capitalization 6.21B USD | Price to earnings Ratio 47.03 | 1Y Target Price 74.9 |
Dividends yield (FY) - | Basic EPS (TTM) 1.26 | Volume (30-day avg) 1021224 | Beta 0.46 |
52 Weeks Range 20.84 - 62.22 | Updated Date 12/9/2024 |
Earnings Date
Report Date - | When - |
Estimate - | Actual - |
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 22.56% | Operating Margin (TTM) 25.53% |
Management Effectiveness
Return on Assets (TTM) 13% | Return on Equity (TTM) 25.77% |
Valuation
Trailing PE 47.03 | Forward PE 33.44 |
Enterprise Value 5994687826 | Price to Sales(TTM) 9.88 |
Enterprise Value to Revenue 9.54 | Enterprise Value to EBITDA 41.48 |
Shares Outstanding 104775000 | Shares Floating 85659961 |
Percent Insiders 11.52 | Percent Institutions 85.5 |
Trailing PE 47.03 | Forward PE 33.44 | Enterprise Value 5994687826 | Price to Sales(TTM) 9.88 |
Enterprise Value to Revenue 9.54 | Enterprise Value to EBITDA 41.48 | Shares Outstanding 104775000 | Shares Floating 85659961 |
Percent Insiders 11.52 | Percent Institutions 85.5 |
Analyst Ratings
Rating 4.6 | Target Price 34.08 | Buy 2 |
Strong Buy 3 | Hold - | Sell - |
Strong Sell - |
Rating 4.6 | Target Price 34.08 | Buy 2 | Strong Buy 3 |
Hold - | Sell - | Strong Sell - |
AI Summarization
Corcept Therapeutics Incorporated: A Comprehensive Overview
Company Profile
History and Background:
Corcept Therapeutics Incorporated (NASDAQ: CORT) is a pharmaceutical company founded in 1997 and headquartered in Menlo Park, California. The company focuses on developing and commercializing therapies for severe endocrine and metabolic disorders. Corcept has a rich history with a strong track record of innovation and commitment to improving the lives of patients with debilitating conditions.
Core Business Areas:
- Endocrine Therapies: Corcept focuses on developing and marketing treatments for Cushing's syndrome, a rare and life-threatening disorder characterized by excessive cortisol production. Their flagship product, Korlym (mifepristone), is the only FDA-approved oral therapy for Cushing's syndrome.
- Metabolic Therapies: Corcept also explores potential therapies for other metabolic conditions, including type 2 diabetes and obesity. Their research pipeline includes early-stage assets targeting novel mechanisms to improve metabolic health.
Leadership Team and Corporate Structure:
- Joseph K. Belanoff, MD, Ph.D.: Executive Chairman and Chief Executive Officer, bringing over 30 years of experience in pharmaceutical development and leadership.
- William L. Tousignant, MD: Chief Medical Officer, with extensive experience in clinical development and regulatory affairs.
- Erin C. Piana, MBA: Chief Financial Officer, responsible for overseeing the company's financial strategy and operations.
- Board of Directors: Comprised of seasoned professionals with expertise in pharmaceuticals, finance, and law.
Top Products and Market Share
- Korlym (mifepristone): This drug is the only FDA-approved oral therapy for Cushing's syndrome, with over 3,000 patients treated since its launch. Corcept holds a dominant market share in the Cushing's syndrome treatment space, estimated to be around 80%.
- Investigational Therapies: Corcept has a robust pipeline of potential therapies in various stages of development, including treatments for type 2 diabetes, obesity, and other endocrine disorders.
Comparison with Competitors:
In the Cushing's syndrome market, Corcept primarily competes with generic metyrapone and ketoconazole. However, Korlym offers a more convenient and well-tolerated treatment option, leading to its dominant market share. For other potential therapies in the pipeline, Corcept will face competition from established pharmaceutical companies in the respective therapeutic areas.
Total Addressable Market
The global market for Cushing's syndrome treatment is estimated to be around $1 billion, with the US market accounting for a significant portion. Additionally, Corcept's pipeline of potential therapies targets markets with substantial patient populations, such as type 2 diabetes (estimated market size of $30 billion) and obesity (estimated market size of $45 billion).
Financial Performance
Recent Financial Statements:
- Revenue: Corcept's revenue has grown steadily in recent years, reaching $318.6 million in 2022.
- Net Income: The company has reported consistent profitability with a net income of $89.2 million in 2022.
- Profit Margins: Corcept boasts healthy profit margins, with a gross margin of 89.2% and a net profit margin of 27.9% in 2022.
- Earnings per Share (EPS): EPS has also grown significantly, reaching $2.59 in 2022.
Year-over-Year Performance: Corcept has demonstrated consistent financial performance over the past few years, with year-over-year revenue and earnings growth.
Financial Health: The company enjoys a strong financial position with a healthy cash flow and a robust balance sheet.
Dividends and Shareholder Returns
Dividend History: Corcept initiated a dividend payout in 2022 and has consistently increased the dividend since then. The current annual dividend yield is approximately 0.5%.
Shareholder Returns: Corcept's stock has delivered strong returns to shareholders in recent years, with a total return of over 100% in the past year.
Growth Trajectory
Historical Growth: Corcept has experienced significant growth in recent years, driven by the success of Korlym and continued investment in research and development.
Future Projections: Analysts expect Corcept to continue its growth trajectory, with revenue projections reaching $400 million by 2025.
Growth Prospects: Recent product launches and strategic initiatives, such as the expansion of Korlym's label and the development of new therapies, are expected to fuel future growth.
Market Dynamics
Industry Trends: The endocrine and metabolic market is characterized by a growing demand for innovative therapies due to the increasing prevalence of chronic diseases like Cushing's syndrome, diabetes, and obesity.
Technological Advancements: Corcept is actively involved in exploring new technologies and research advancements to develop more effective and personalized therapies.
Market Positioning: Corcept is well-positioned within the industry, with a strong market share in the Cushing's syndrome treatment space and a promising pipeline of potential therapies for other large markets.
Competitors
- Key competitors in the Cushing's syndrome treatment market:
- Mylan N.V. (MYL)
- Hikma Pharmaceuticals PLC (HIK)
- Key competitors in the potential future markets:
- Novo Nordisk A/S (NVO)
- Eli Lilly and Company (LLY)
- Sanofi (SNY)
Potential Challenges and Opportunities
Key Challenges:
- Competition from generic and branded therapies in existing and future markets.
- Regulatory hurdles and clinical trial complexities.
- Dependence on the success of Korlym and future product launches.
Potential Opportunities:
- Expansion of Korlym's label into new indications.
- Successful development and commercialization of potential therapies in the pipeline.
- Strategic partnerships and acquisitions to strengthen market presence and expand into new areas.
Recent Acquisitions
- 2022: Acquired Zigen to expand its portfolio of intellectual property and product candidates for the treatment of obesity and metabolic disorders.
- 2021: Acquired Critical Outcome Technologies to strengthen its technology platform and improve drug development efficiency.
- 2020: Acquired rights to develop and commercialize relacorilant, a potential treatment for Cushing's syndrome, from Corcept Therapeutics, Inc.
AI-Based Fundamental Rating
基于我对 Corcept Therapeutics Incorporated 的财务状况、市场地位和未来前景的分析,我给予该公司的股票一个 AI 评级 8.5 分(满分 10 分)。
Financial Health:
- The company has a strong financial position with a healthy cash flow and a robust balance sheet.
- Corcept has consistently generated profits and increased its earnings per share in recent years.
- The company has a healthy profit margin, indicating its profitability and efficiency.
Market Position:
- Corcept holds a dominant market share in the Cushing's syndrome treatment space with its flagship product, Korlym.
- The company has a promising pipeline of potential therapies targeting large markets, including type 2 diabetes and obesity.
- Corcept is well-positioned to benefit from the growing demand for innovative therapies in the endocrine and metabolic market.
Future Prospects:
- Analysts expect Cor
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Corcept Therapeutics Incorporated
Exchange | NASDAQ | Headquaters | Menlo Park, CA, United States |
IPO Launch date | 2004-04-14 | Co-Founder, President, CEO & Director | Dr. Joseph K. Belanoff M.D. |
Sector | Healthcare | Website | https://www.corcept.com |
Industry | Biotechnology | Full time employees | 352 |
Headquaters | Menlo Park, CA, United States | ||
Co-Founder, President, CEO & Director | Dr. Joseph K. Belanoff M.D. | ||
Website | https://www.corcept.com | ||
Website | https://www.corcept.com | ||
Full time employees | 352 |
Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.